Innovative Scanner Enables Early Detection of Bedsores, Enhancing Patient Care and Reducing Healthcare Costs

A revolutionary handheld scanner now detects bedsores early, preventing complications, saving lives, and reducing healthcare costs by providing a more equitable and accurate assessment for diverse patient populations.
Recent advancements in wound assessment technology have led to the development of a groundbreaking handheld scanner that detects pressure ulcers, commonly known as bedsores, at an earlier stage than ever before. This innovation promises to save lives and significantly cut healthcare expenses associated with the treatment of these preventable wounds.
The scanner was inspired by a challenging case in 2010, when UCLA nursing professor Barbara Bates-Jensen traveled to Haiti to provide wound care following a devastating earthquake. There, she encountered patients suffering from severe pressure injuries, many of which had been untreated for weeks. Recognizing the limitations of traditional visual inspection— which often detects damage only after visible skin discoloration appears— Bates-Jensen and her team sought a more reliable and equitable method.
Each year, approximately 2.5 million individuals in the U.S. develop bedsores, with some 60,000 succumbing to related complications. The healthcare system spends over $11 billion annually managing these wounds, which are 95% preventable through proper care. Traditional detection relies heavily on identifying skin discoloration; however, this approach is subjective and less effective for patients with darker skin tones, who are at higher risk of severe pressure ulcers.
The new device, known as the SEM Scanner, measures moisture levels within tissues—a biophysical marker of early tissue damage—indicating the onset of pressure injuries up to 10 days before visible signs emerge. Unlike visual assessments, it doesn’t depend on skin color, making it a more equitable tool for diverse patient populations. Developed through collaboration with UCLA computer scientists and engineers, the SEM Scanner has been adopted in hospitals across Europe, the U.K., Canada, and the U.S., with over a million patients benefiting from the technology and an estimated 50,000 pressure injuries prevented.
Currently, UCLA researcher and associate dean Barbara Bates-Jensen is involved in studies aiming to expand the use of this device beyond hospitals—for instance, into nursing homes—enhancing care for vulnerable residents. The goal is to improve early detection, streamline interventions, and address disparities related to skin tone, ultimately fostering more equitable healthcare outcomes.
The SEM Scanner's success exemplifies how innovative medical technology can transform wound care by enabling earlier diagnosis, reducing suffering, and improving health equity. As it continues to spread globally, this device represents a significant step toward more proactive and inclusive patient care.
For further information, source: https://medicalxpress.com/news/2025-09-scanner-bedsores-earlier.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Insights Into How Bowel Cancer Develops Drug Resistance
Researchers uncover how epigenetic changes enable bowel cancer cells to develop resistance to treatments, paving the way for more targeted therapies.
Low Pre-Pregnancy Blood Sugar Levels Associated with Increased Risks During Pregnancy
Research shows that low blood sugar levels before conception are linked to higher risks of preterm birth, low birth weight, and other pregnancy complications, emphasizing the need for preconception screening.
FDA Approves Innovative Eye Implant to Combat Vision Loss in Rare Retina Disease
The FDA has approved ENCELTO, a groundbreaking eye implant that slows vision loss in patients with macular telangiectasia type 2, offering hope through advanced neuroprotective therapy.
Understanding How Viruses Exploit Weaknesses in Antibody Defense
Recent research reveals how SARS-CoV-2 develops mutations to evade monoclonal antibody treatments. Combining multiple antibodies could prevent viral escape and improve therapeutic efficacy.



